These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28854670)

  • 21. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
    Kuti JL; Horowitz S; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa.
    Zhanel GG; Mayer M; Laing N; Adam HJ
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2228-30. PubMed ID: 16723591
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimicrobial activity of commonly used antibiotics and DNA fingerprint analysis of Pseudomonas aeruginosa obtained from clinical isolates and unchlorinated drinking water in Korea, 2010.
    Kim JR; Lee DK; An HM; Kim MJ; Lee SW; Cha MK; Lee KO; Ha NJ
    Arch Pharm Res; 2011 Aug; 34(8):1353-61. PubMed ID: 21910058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
    Livermore DM; Chen HY
    J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates.
    Buehrle DJ; Shields RK; Chen L; Hao B; Press EG; Alkrouk A; Potoski BA; Kreiswirth BN; Clancy CJ; Nguyen MH
    Antimicrob Agents Chemother; 2016 May; 60(5):3227-31. PubMed ID: 26976862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012-15.
    Kazmierczak KM; de Jonge BLM; Stone GG; Sahm DF
    J Antimicrob Chemother; 2018 Oct; 73(10):2777-2781. PubMed ID: 30010951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
    Erdem I; Kaynar-Tascioglu J; Kaya B; Goktas P
    Int J Antimicrob Agents; 2002 Nov; 20(5):384-6. PubMed ID: 12431875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa.
    Hikida M; Yamazaki Y; Yoshida M; Kawashima K; Nishiki K; Mitsuhashi S
    J Antibiot (Tokyo); 1995 Aug; 48(8):891-2. PubMed ID: 7592037
    [No Abstract]   [Full Text] [Related]  

  • 30. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
    Nasu Y; Abe M; Ono N; Araki M; Horimi T; Takahashi I
    Jpn J Antibiot; 2004 Oct; 57(5):438-48. PubMed ID: 15655905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa.
    Shibata K; Adachi Y; Kato E; Nagano R; Fuse A; Hashizume T; Ohtake N; Okamoto O; Nakagawa S
    J Antibiot (Tokyo); 1997 Feb; 50(2):135-8. PubMed ID: 9099222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro efficacy of various antibiotic combinations against Pseudomonas aeruginosa isolates.
    Nazli E; Zer Y; Eksi F
    J Int Med Res; 2015 Apr; 43(2):217-25. PubMed ID: 25547417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Molecular epidemiology of beta-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates].
    Er H; Altındiş M; Aşık G; Demir C
    Mikrobiyol Bul; 2015 Apr; 49(2):156-65. PubMed ID: 26167816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Balke B; Hogardt M; Schmoldt S; Hoy L; Weissbrodt H; Häussler S
    Eur J Clin Microbiol Infect Dis; 2006 Jan; 25(1):25-30. PubMed ID: 16402226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M; Fàbrega A; Cobos-Trigueros N; Zamorano L; Ferrer-Navarro M; Ballesté-Delpierre C; Reustle A; Castro P; Nicolás JM; Oliver A; Martínez JA; Vila J
    J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects.
    Trautmann M; Heinemann M; Zick R; Möricke A; Seidelmann M; Berger D
    Eur J Clin Microbiol Infect Dis; 1998 Nov; 17(11):754-60. PubMed ID: 9923514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
    Grupper M; Sutherland C; Nicolau DP
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In-vitro activity of meropenem, a new carbapenem, against multiresistant Pseudomonas aeruginosa compared with that of other antipseudomonal antimicrobials.
    Voutsinas D; Mavroudis T; Avlamis A; Giamarellou H
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():143-7. PubMed ID: 2509412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections.
    Ermertcan S; Hoşgör M; Tünger O; Coşar G
    Scand J Infect Dis; 2001; 33(11):818-21. PubMed ID: 11760161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group.
    Goossens H
    Clin Microbiol Infect; 2003 Sep; 9(9):980-3. PubMed ID: 14616692
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.